Two doses per year could reshape HIV prevention, but price and licensing issues may limit scalability within the Brazilian public health system (SUS). The “quasi-vaccine” developed by Gilead Sciences arrives in Brazil with rare clinical evidence and global regulatory endorsement. But the geopolitics of voluntary licenses and the pricing logic in rich markets create a dilemma: how to remunerate innovation without turning prevention into a luxury incompatible with universality

How to revive the cooperative model that can transform Brazil into a biotechnology powerhouse When I received the invitation in 2005 to...

The global pharmaceutical and biotechnology industry is experiencing a period of accelerated growth in drug use and spending, driven by...

In June 2025, the US Food and Drug Administration approved a new HIV pre-exposure prophylaxis (PrEP) regimen: the long-acting injectable...

The emergence of cutting-edge technologies, known as deeptechs, marks a new phase in global innovation. These technologies, which emerge...

In recent years, I’ve had the privilege of closely following the birth and growth of dozens of health startups, both in Brazil and...

In the contemporary global landscape, the concept of an isolated national economy has become a fiction. Nations do not compete solely for...

Health innovation and the remarkable growth of the pharmaceutical sector—with a projected global revenue of USD 1.155 trillion in...